A pilot study of the pan‐class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer-Reference-Cited by-同舟云学术

A pilot study of the pan‐class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer

Published:2019-09-04 Issue:11 Volume:41 Page:3842-3849
ISSN:1043-3074
Container-title:Head & Neck
language:en
Short-container-title:Head & Neck

Author:

Brisson Ryan J.¹^ORCID,Kochanny Sara²,Arshad Saba³,Dekker Allison²,DeSouza Jonas A.⁴,Saloura Vassiliki⁵,Vokes Everett E.²⁶,Seiwert Tanguy Y.²⁶

Affiliation:

1. Oakland University William Beaumont School of Medicine Rochester Michigan

2. Department of MedicineThe University of Chicago Medicine Chicago Illinois

3. Department of MedicineBlake Medical Center Bradenton Florida

4. Humana Louisville Kentucky

5. National Cancer InstituteNational Institutes of Health Bethesda Maryland

6. The University of Chicago Comprehensive Cancer Center Chicago Illinois

Publisher

Wiley

Subject

Otorhinolaryngology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hed.25910

Reference20 articles.

1. Genetic Landscape of Human Papillomavirus–Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors

2. Cancer statistics, 2018

3. Epidermal Growth Factor Receptor Expression in Pretreatment Biopsies From Head and Neck Squamous Cell Carcinoma As a Predictive Factor for a Benefit From Accelerated Radiation Therapy in a Randomized Controlled Trial

4. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma;Ang KK;Cancer Res,2002

5. VermorkenJB MesiaR RiveraF et al.Platinum‐based chemotherapy plus cetuximab in head and neck cancer.2008;359(11):1116‐1127.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review of contemporary phase I trials in patients with recurrent/metastatic head and neck cancer;Oral Oncology Reports;2024-09

2. EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma;International Journal of Molecular Sciences;2024-05-20

3. Clinical and genomic characterization of chemoradiation-resistant HPV-positive oropharyngeal squamous cell carcinoma;Frontiers in Oncology;2024-03-05

4. Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers;International Journal of Molecular Sciences;2024-02-06

5. A systematic literature review of the human papillomavirus prevalence in locally and regionally advanced and recurrent/metastatic head and neck cancers through the last decade: The “ALARM” study;Cancer Medicine;2024-01-21